Literature DB >> 12634242

Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis.

P Verschueren, F Lensen, E Lerut, K Claes, R De Vos, B Van Damme, R Westhovens.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12634242      PMCID： PMC1754503          DOI： 10.1136/ard.62.4.368

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  4 in total

1.  Tumor necrosis factor-alpha blocking agent as a treatment for nephrotic syndrome.

Authors:  David Raveh; Ovadia Shemesh; Yaakov Jack Ashkenazi; Robert Winkler; Vivian Barak
Journal:  Pediatr Nephrol       Date:  2004-08-25       Impact factor: 3.714

2.  A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab.

Authors:  Takeshi Kuroda; Yasuhiro Otaki; Hiroe Sato; Takeo Fujimura; Takeshi Nakatsue; Syuichi Murakami; Minoru Sakatsume; Masaaki Nakano; Fumitake Gejyo
Journal:  Rheumatol Int       Date:  2008-05-22       Impact factor: 2.631

3.  Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury.

Authors:  Alaa S Awad; Hanning You; Ting Gao; Timothy K Cooper; Sergei A Nedospasov; Jean Vacher; Patrick F Wilkinson; Francis X Farrell; W Brian Reeves
Journal:  Kidney Int       Date:  2015-06-10       Impact factor: 10.612

Review 4.  Management of cutaneous disorders related to inflammatory bowel disease.

Authors:  Zaira Pellicer; Jesus Manuel Santiago; Alejandro Rodriguez; Vicent Alonso; Rosario Antón; Marta Maia Bosca
Journal:  Ann Gastroenterol       Date:  2012
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.